APR Applied Pharma Research S.A. Receive IND Approval From FDA for a New NSAID Matrix Patch Product

BALERNA, Switzerland & ABANO TERME (PD), Italy--(BUSINESS WIRE)--Applied Pharma Research sa (APR), and Fidia Farmaceutici SpA (Fidia) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for the development of a 140mg Diclofenac Sodium Matrix Patch for the topical treatment of acute pain due to minor strains, sprains and contusions.
MORE ON THIS TOPIC